81 Cell Therapy (CAR-T / NK / TIL) CRO and CDMO vendors

What does it take to develop and manufacture a Cell Therapy (CAR-T / NK / TIL) drug?

Cell therapy is the hardest CMC problem in the modality landscape, and the work spreads across more vendors than most teams expect at the outset. On the discovery and preclinical side you are validating a construct (the CAR design, the costimulatory domains, the cell source), running in vitro potency and cytotoxicity assays, and pushing toward IND-enabling tox in a relevant model. Cell products do not behave like small molecules in tox studies, so you often need a CRO that has actually run studies on a living cell drug rather than one that treats it as another biologic.

The center of gravity, though, is manufacturing. An autologous CAR-T process starts from a patient apheresis, runs through activation, viral transduction, expansion, formulation, and cryopreservation, and every one of those steps has to be locked down, characterized, and made reproducible across operators and sites. Allogeneic NK and TIL programs change the math: you are building a scalable, donor-derived or expanded process where consistency across a much larger batch matters more than turnaround on a single patient. Either way you need vector. Most CAR-T and many gene-modified NK programs depend on a lentiviral or retroviral vector, which means a viral vector manufacturing slot (and the plasmid DNA upstream of it) is on your critical path long before you reach clinical supply.

This is where specialist CDMOs separate from generalists. A generalist biologics shop can run a bioreactor and fill vials; far fewer have validated, GMP-grade closed-system cell processing, cryo logistics, a chain-of-identity and chain-of-custody system tying a product back to the right patient, and the potency and flow-based release panels regulators now expect for a cell drug. Analytical capability is the quiet differentiator: vector copy number, transduction efficiency, viability, identity, sterility, mycoplasma, endotoxin, and a potency assay that actually predicts clinical activity. A vendor that has filed this package before, and survived the agency questions that come with it, saves you months you cannot get back.

How do you choose a CRO or CDMO for Cell Therapy (CAR-T / NK / TIL)?

Vendor selection for cell therapy rewards specificity. The right partner for an autologous CAR-T is often the wrong one for an allogeneic NK platform, so screen against your exact process, scale, and regulatory path rather than a generic capability list. Use the checklist below as a starting screen, then go deep with the two or three vendors that survive it.

• Relevant platform and track record: have they run your specific format (autologous CAR-T, allogeneic NK, TIL) through process development and GMP, not just adjacent gene therapy work? Ask for the cell types and constructs they have actually handled.
• GxP and analytical capability for this modality: validated GMP cleanrooms or closed/isolator systems, plus an analytical team that owns vector copy number, transduction efficiency, viability, identity, sterility, mycoplasma, and a real potency assay, not outsourced piecemeal.
• Vector and starting-material supply: in-house or reliably sourced lentiviral or retroviral vector and plasmid DNA, with timeline and slot availability that fits your clinical schedule, since vector lead times often dominate the program.
• Capacity and scale: enough suites and cryo capacity to run your batch cadence today and a credible path to commercial scale, whether that is many small autologous runs or fewer large allogeneic lots.
• Regulatory experience: prior INDs, BLAs, or comparable filings for cell products, familiarity with FDA and EMA expectations for potency and comparability, and the ability to author or support the CMC sections rather than hand you raw data.
• Chain of identity and logistics: a documented chain-of-identity and chain-of-custody system, cryopreservation and cold-chain handling, and apheresis or starting-material coordination that will not break under clinical timelines.
• IP and data ownership: clear terms that your process know-how, cell lines, and analytical methods remain yours, with no claim on your construct or downstream rights.